Drugs / NNC0638-0355
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06577766 | Sep 2024 → Sep 2026 overdue | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0638-0355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577766 ↗ |
| Route | Subcutaneous | “NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.” NCT06577766 ↗ |